BE759838A
(fr)
|
1969-12-04 |
1971-06-03 |
Wellcome Found |
Cetones a activite biologique
|
US3885046A
(en)
|
1969-12-04 |
1975-05-20 |
Burroughs Wellcome Co |
Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
|
US3942641A
(en)
|
1972-05-05 |
1976-03-09 |
Syntex Corporation |
Dispensing packages containing novel cyclic progestogen-interrupted estrogen oral contraceptive regimens
|
US4089855A
(en)
|
1976-04-23 |
1978-05-16 |
Cornell Research Foundation, Inc. |
Process for the stereoselective reduction of 6- and 8-keto morphine and morphinan derivatives with formamidinesulfinic acid and compounds obtained thereby
|
US4218433A
(en)
|
1977-03-03 |
1980-08-19 |
Nippon Kayaku Kabushiki Kaisha |
Constant-rate eluting tablet and method of producing same
|
US4217353A
(en)
*
|
1978-05-19 |
1980-08-12 |
E. I. Du Pont De Nemours And Company |
Method for inducing anorexia
|
US4172896A
(en)
|
1978-06-05 |
1979-10-30 |
Dainippon Pharmaceutical Co., Ltd. |
Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
|
US4214081A
(en)
|
1978-06-19 |
1980-07-22 |
E. R. Squibb & Sons, Inc. |
Imino containing morpholine compounds
|
IL58649A
(en)
|
1978-11-10 |
1982-04-30 |
Beecham Group Ltd |
Pharmaceutical dispensing container
|
ZA824382B
(en)
|
1981-07-07 |
1984-02-29 |
Wyeth John & Brother Ltd |
Anti-obesity agents
|
JPS58134019A
(ja)
|
1982-02-05 |
1983-08-10 |
Ono Pharmaceut Co Ltd |
プロスタグランジン含有持続放出型三層状フイルム製剤及びその製造方法
|
JPS59500418A
(ja)
|
1982-03-16 |
1984-03-15 |
ザ ロツクフエラ− ユニバ−シテイ |
胃腸能動作用障害を回復する方法
|
US4513006A
(en)
|
1983-09-26 |
1985-04-23 |
Mcneil Lab., Inc. |
Anticonvulsant sulfamate derivatives
|
US5266574A
(en)
|
1984-04-09 |
1993-11-30 |
Ian S. Zagon |
Growth regulation and related applications of opioid antagonists
|
US4689332A
(en)
|
1984-04-09 |
1987-08-25 |
Research Corporation |
Growth regulation and related applications of opioid antagonists
|
US4673679A
(en)
|
1986-05-14 |
1987-06-16 |
E. I. Du Pont De Nemours And Company |
Use of prodrugs of 3-hydroxymorphinans to prevent bitter taste upon buccal, nasal or sublingual administration
|
GB8613689D0
(en)
|
1986-06-05 |
1986-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
US4895845A
(en)
|
1986-09-15 |
1990-01-23 |
Seed John C |
Method of assisting weight loss
|
NL8800823A
(nl)
|
1987-04-10 |
1988-11-01 |
Sandoz Ag |
Werkwijze voor het toepassen van dopamine-receptor agonisten en farmaceutische preparaten die deze agonisten bevatten.
|
EP0294028B1
(de)
|
1987-05-04 |
1993-09-01 |
Eli Lilly And Company |
Verwendung von Fluoxetin zur Behandlung des Diabetes
|
US5000886A
(en)
|
1987-05-26 |
1991-03-19 |
American Cyanamid Company |
Silicone-hardened pharmaceutical microcapsules and process of making the same
|
US5364841A
(en)
|
1988-01-11 |
1994-11-15 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and essential hypertension and related disorders
|
US4831031A
(en)
|
1988-01-22 |
1989-05-16 |
Pfizer Inc. |
Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
|
US5719197A
(en)
|
1988-03-04 |
1998-02-17 |
Noven Pharmaceuticals, Inc. |
Compositions and methods for topical administration of pharmaceutically active agents
|
US5202128A
(en)
|
1989-01-06 |
1993-04-13 |
F. H. Faulding & Co. Limited |
Sustained release pharmaceutical composition
|
US5114976A
(en)
|
1989-01-06 |
1992-05-19 |
Norden Michael J |
Method for treating certain psychiatric disorders and certain psychiatric symptoms
|
WO1990013294A1
(en)
|
1989-05-09 |
1990-11-15 |
Whitby Research, Inc. |
A method of reducing body weight and food intake using a dopamine d2 receptor agonist
|
DK469989D0
(da)
|
1989-09-22 |
1989-09-22 |
Bukh Meditec |
Farmaceutisk praeparat
|
ES2062310T3
(es)
|
1989-12-06 |
1994-12-16 |
Akzo Nv |
Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
|
FR2657350B1
(fr)
|
1990-01-19 |
1992-05-15 |
Centre Nat Rech Scient |
Composes destines a l'encapsulation dans les erythrocytes - nouveaux derives de la naloxone et naltrexone.
|
US5028612A
(en)
|
1990-03-22 |
1991-07-02 |
Hillel Glover |
Method for treating emotional numbness
|
US5213807A
(en)
|
1990-05-03 |
1993-05-25 |
Chemburkar Pramod B |
Pharmaceutical composition containing ibuprofen and a prostaglandin
|
US5486362A
(en)
*
|
1991-05-07 |
1996-01-23 |
Dynagen, Inc. |
Controlled, sustained release delivery system for treating drug dependency
|
US5403595A
(en)
*
|
1991-05-07 |
1995-04-04 |
Dynagen, Inc. |
Controlled, sustained release delivery system for smoking cessation
|
DE4136215A1
(de)
|
1991-11-02 |
1993-05-06 |
Ferring Arzneimittel Gmbh, 2300 Kiel, De |
Verwendung von opiat-antagonisten zur behandlung von endogener hyperinsulinaemie
|
GB9217295D0
(en)
|
1992-08-14 |
1992-09-30 |
Wellcome Found |
Controlled released tablets
|
US5312925A
(en)
|
1992-09-01 |
1994-05-17 |
Pfizer Inc. |
Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
|
IT1255522B
(it)
|
1992-09-24 |
1995-11-09 |
Ubaldo Conte |
Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
|
IT1256393B
(it)
|
1992-11-17 |
1995-12-04 |
Inverni Della Beffa Spa |
Forme matriciali multistrato per il rilascio controllato di principi attivi
|
US5512593A
(en)
|
1993-03-02 |
1996-04-30 |
John S. Nagle |
Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
|
GB9315856D0
(en)
|
1993-07-30 |
1993-09-15 |
Wellcome Found |
Stabilized pharmaceutical
|
US5541231A
(en)
|
1993-07-30 |
1996-07-30 |
Glaxo Wellcome Inc. |
Stabilized Pharmaceutical
|
US5358970A
(en)
|
1993-08-12 |
1994-10-25 |
Burroughs Wellcome Co. |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US6183778B1
(en)
|
1993-09-21 |
2001-02-06 |
Jagotec Ag |
Pharmaceutical tablet capable of liberating one or more drugs at different release rates
|
IT1265240B1
(it)
|
1993-11-30 |
1996-10-31 |
Ekita Investments Nv |
Compressa farmaceutica a rilascio controllato, di forma lenticolare
|
ATE214276T1
(de)
|
1994-09-19 |
2002-03-15 |
Du Pont Pharm Co |
Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
|
US5627187A
(en)
|
1995-04-12 |
1997-05-06 |
Katz; Bruce E. |
5-FU for treating actinic kerotoses
|
US5714519A
(en)
|
1995-06-07 |
1998-02-03 |
Ergo Science Incorporated |
Method for regulating glucose metabolism
|
WO1997006787A2
(en)
|
1995-08-17 |
1997-02-27 |
Dyer, Alison, Margaret |
Controlled release products
|
GB9517062D0
(en)
|
1995-08-18 |
1995-10-25 |
Scherer Ltd R P |
Pharmaceutical compositions
|
US5713488A
(en)
*
|
1996-01-24 |
1998-02-03 |
Farrugia; John V. |
Condom dispenser
|
WO1997033566A2
(en)
|
1996-03-12 |
1997-09-18 |
Alza Corporation |
Composition and dosage form comprising opioid antagonist
|
EP0795327A1
(de)
|
1996-03-13 |
1997-09-17 |
Pfizer Inc. |
Verwendung von Amlodipin zur Behandlung von Prophylaxe von kongestivem Herzversagen nichtischämischen Ursprungs
|
AU724993B2
(en)
|
1996-03-13 |
2000-10-05 |
Yale University |
Smoking cessation treatments using naltrexone and related compounds
|
US5716976A
(en)
|
1996-03-13 |
1998-02-10 |
Bernstein; Richard K. |
Method of treatment for carbohydrate addiction
|
US20040024006A1
(en)
|
1996-05-06 |
2004-02-05 |
Simon David Lew |
Opioid pharmaceutical compositions
|
ATE344668T1
(de)
|
1996-05-07 |
2006-11-15 |
Pliva Istrazivanje I Razvoj D |
Verfahren und zusammensetzung zur behandlung von stoerungen des fett- und glukosemetabolismus
|
IL121076A
(en)
|
1996-06-19 |
2000-10-31 |
Akzo Nobel Nv |
Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
|
US6087386A
(en)
|
1996-06-24 |
2000-07-11 |
Merck & Co., Inc. |
Composition of enalapril and losartan
|
AU732923B2
(en)
|
1996-06-28 |
2001-05-03 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant sulfamate derivatives useful in treating obesity
|
US5878750A
(en)
|
1996-11-14 |
1999-03-09 |
Clemens; Anton H. |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
FR2758723B1
(fr)
|
1997-01-28 |
1999-04-23 |
Sanofi Sa |
Utilisation des antagonistes des recepteurs aux cannabinoides centraux pour la preparation de medicaments
|
CA2216215A1
(en)
|
1997-04-05 |
1998-10-05 |
Isa Odidi |
Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
|
ES2234139T3
(es)
|
1997-08-11 |
2005-06-16 |
Alza Corporation |
Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
|
US6622036B1
(en)
|
2000-02-09 |
2003-09-16 |
Cns Response |
Method for classifying and treating physiologic brain imbalances using quantitative EEG
|
DE69811378T2
(de)
*
|
1997-10-03 |
2004-02-12 |
Cary Pharmaceuticals Inc. (n.d.Ges.d. Staates Delaware) |
Zusammensetzungen zur behandlung von nikotinabhängigkeit, enthaltend mecamylamin und bupropion
|
US6652882B1
(en)
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US6262049B1
(en)
|
1997-10-28 |
2001-07-17 |
Schering Corporation |
Method of reducing nicotine and tobacco craving in mammals
|
IL127497A
(en)
|
1997-12-18 |
2002-07-25 |
Pfizer Prod Inc |
Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
|
CA2317044C
(en)
|
1997-12-26 |
2008-02-26 |
Dainippon Pharmaceutical Co., Ltd. |
Medicament for neurodegenerative diseases
|
EP1829544A1
(de)
|
1998-01-21 |
2007-09-05 |
Glaxo Group Limited |
Pharmazeutisch aktives Morpholinol
|
AU2483599A
(en)
|
1998-01-29 |
1999-08-16 |
Sepracor, Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
US6048322A
(en)
|
1998-04-15 |
2000-04-11 |
Kushida; Clete |
Morphometric measurement tool
|
US6153223A
(en)
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
US6150366A
(en)
|
1998-06-15 |
2000-11-21 |
Pfizer Inc. |
Ziprasidone formulations
|
US8236352B2
(en)
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US6096341A
(en)
|
1998-10-30 |
2000-08-01 |
Pharma Pass Llc |
Delayed release tablet of bupropion hydrochloride
|
US6033686A
(en)
|
1998-10-30 |
2000-03-07 |
Pharma Pass Llc |
Controlled release tablet of bupropion hydrochloride
|
EP1005863A1
(de)
|
1998-12-04 |
2000-06-07 |
Synthelabo |
Dosisformen mit gesteuerter Wirkstofffreigabe enthaltend ein kurzer wirkung Hypnotikum oder einem Salz davon
|
US20030144174A1
(en)
|
1998-12-09 |
2003-07-31 |
Miles B. Brennan |
Methods for identifying compounds useful for the regulation of body weight and associated conditions
|
US6238697B1
(en)
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6635281B2
(en)
|
1998-12-23 |
2003-10-21 |
Alza Corporation |
Gastric retaining oral liquid dosage form
|
US6797283B1
(en)
|
1998-12-23 |
2004-09-28 |
Alza Corporation |
Gastric retention dosage form having multiple layers
|
US6706283B1
(en)
|
1999-02-10 |
2004-03-16 |
Pfizer Inc |
Controlled release by extrusion of solid amorphous dispersions of drugs
|
US6323236B2
(en)
|
1999-02-24 |
2001-11-27 |
University Of Cincinnati |
Use of sulfamate derivatives for treating impulse control disorders
|
US6589553B2
(en)
*
|
2001-02-08 |
2003-07-08 |
Andrx Pharmaceuticals, Inc. |
Controlled release oral dosage form
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
US20030035840A1
(en)
|
2001-02-08 |
2003-02-20 |
Boyong Li |
Controlled release oral dosage form
|
US6210716B1
(en)
*
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US8545880B2
(en)
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6342496B1
(en)
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6387956B1
(en)
|
1999-03-24 |
2002-05-14 |
University Of Cincinnati |
Methods of treating obsessive-compulsive spectrum disorders
|
ATE384035T1
(de)
|
1999-04-01 |
2008-02-15 |
Esperion Therapeutics Inc |
Ether-verbindungen, zusammensetzungen und ihre verwendung
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
EP1905757A1
(de)
|
1999-04-06 |
2008-04-02 |
Sepracor Inc. |
Derivate von Venlafaxin und Verfahren zu ihrer Herstellung und Verwendung
|
NZ514811A
(en)
|
1999-04-08 |
2005-01-28 |
Ortho Mcneil Pharm Inc |
Anticonvulsant derivatives useful in reducing blood glucose levels
|
GB9908921D0
(en)
|
1999-04-19 |
1999-06-16 |
Britannia Pharmaceuticals Ltd |
Spray dispenser for opiod antagonists
|
US6420369B1
(en)
|
1999-05-24 |
2002-07-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful in treating dementia
|
EP2305226B1
(de)
|
1999-06-14 |
2015-05-06 |
Vivus, Inc. |
Kombinationstherapie zur Behandlung von Schlafapnoe bei Fettleibigkeit
|
US7056890B2
(en)
|
1999-06-14 |
2006-06-06 |
Vivus, Inc. |
Combination therapy for effecting weight loss and treating obesity
|
DE19927688A1
(de)
|
1999-06-17 |
2000-12-21 |
Gruenenthal Gmbh |
Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
|
US20040115134A1
(en)
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
HUP0201623A3
(en)
|
1999-07-01 |
2004-12-28 |
Upjohn Co |
Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
|
US6071918A
(en)
*
|
1999-07-21 |
2000-06-06 |
Dupont Pharmaceuticals Company |
Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
|
US6500459B1
(en)
|
1999-07-21 |
2002-12-31 |
Harinderpal Chhabra |
Controlled onset and sustained release dosage forms and the preparation thereof
|
CO5210862A1
(es)
|
1999-09-15 |
2002-10-30 |
Alza Corp |
Formas de dosificacion y metodos para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia
|
WO2001019321A2
(en)
|
1999-09-15 |
2001-03-22 |
Elan Pharmaceuticals, Inc. |
Methods for treating neuropathic pain using hetreoarylmethanesulfonamides
|
US6403657B1
(en)
|
1999-10-04 |
2002-06-11 |
Martin C. Hinz |
Comprehensive pharmacologic therapy for treatment of obesity
|
GB2355191A
(en)
|
1999-10-12 |
2001-04-18 |
Laxdale Ltd |
Combination formulations for fatigue, head injury and strokes
|
AU7750100A
(en)
|
1999-10-13 |
2001-04-23 |
Glaxo Group Limited |
Method for the treatment of obesity
|
US6410736B1
(en)
|
1999-11-29 |
2002-06-25 |
Pfizer Inc. |
Biaryl ether derivatives useful as monoamine reuptake inhibitors
|
AR031682A1
(es)
|
1999-11-19 |
2003-10-01 |
Reckitt Benckiser Helthcare Uk |
Composiciones farmaceuticas
|
US20020055512A1
(en)
|
2000-01-21 |
2002-05-09 |
Cortendo Ab. |
Compositions for delivery of a cortisol antagonist
|
GB0001449D0
(en)
|
2000-01-21 |
2000-03-08 |
Cortendo Ab |
Compositions
|
WO2001052851A1
(en)
*
|
2000-01-22 |
2001-07-26 |
Albert Shulman |
Methods for the treatment of substance abuse
|
CN1406129A
(zh)
*
|
2000-01-22 |
2003-03-26 |
艾伯特·舒尔曼 |
用于治疗物质滥用的方法
|
US20020090615A1
(en)
|
2000-01-31 |
2002-07-11 |
Rosen Craig A. |
Nucleic acids, proteins, and antibodies
|
JP2003522144A
(ja)
|
2000-02-08 |
2003-07-22 |
ユーロ−セルティーク,エス.エイ. |
オピオイドアゴニストおよびアンタゴニストを含む制御放出組成物
|
US6627223B2
(en)
|
2000-02-11 |
2003-09-30 |
Eurand Pharmaceuticals Ltd. |
Timed pulsatile drug delivery systems
|
ATE326222T1
(de)
|
2000-03-15 |
2006-06-15 |
Wolfgang Sadee |
Naloxon- und naltrexon-analoga in der behandlung bei drogenmissbrauch
|
EP1274444B1
(de)
|
2000-03-16 |
2013-05-15 |
THE McLEAN HOSPITAL CORPORATION |
Cdp-cholin und uridin zur behandlung von alkoholmissbrauch
|
US6437147B1
(en)
|
2000-03-17 |
2002-08-20 |
Novo Nordisk |
Imidazole compounds
|
WO2001078725A2
(en)
|
2000-04-13 |
2001-10-25 |
Synthon B.V. |
Modified release formulations containing a hypnotic agent
|
AU2001250646A1
(en)
|
2000-04-17 |
2001-10-30 |
Yamanouchi Pharmaceutical Co..Ltd. |
Drug delivery system for avoiding pharmacokinetic interaction between drugs and method thereof
|
US6761895B2
(en)
|
2000-04-17 |
2004-07-13 |
Yamanouchi Pharmaceutical Co., Ltd. |
Drug delivery system for averting pharmacokinetic drug interaction and method thereof
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
JP2004515455A
(ja)
|
2000-05-05 |
2004-05-27 |
ペイン・セラピューティクス・インコーポレイテッド |
オピオイドアンタゴニスト組成物および投薬形態
|
US20020044962A1
(en)
|
2000-06-06 |
2002-04-18 |
Cherukuri S. Rao |
Encapsulation products for controlled or extended release
|
US6191117B1
(en)
|
2000-07-10 |
2001-02-20 |
Walter E. Kozachuk |
Methods of producing weight loss and treatment of obesity
|
US6627653B2
(en)
|
2000-08-02 |
2003-09-30 |
Ortho-Mcneil Pharmaceutical, Inc. |
Anticonvulsant derivatives useful for the treatment of depression
|
US6528520B2
(en)
|
2000-08-15 |
2003-03-04 |
Cpd, Llc |
Method of treating the syndrome of coronary heart disease risk factors in humans
|
JP5161412B2
(ja)
|
2000-09-18 |
2013-03-13 |
サノス・バイオサイエンス・アクティーゼルスカブ |
Glp−1及びglp−2ペプチドの使用方法
|
RU2003112618A
(ru)
|
2000-10-30 |
2004-09-27 |
Орто-Макнейл Фармасьютикал, Инк. (Us) |
Комбинированная терапия, включающая антидиабетические и противосудорожные средства
|
RU2197250C2
(ru)
|
2000-10-30 |
2003-01-27 |
Соколовский Сергей Ростиславович |
Способ лечения наркоманий
|
US6569449B1
(en)
|
2000-11-13 |
2003-05-27 |
University Of Kentucky Research Foundation |
Transdermal delivery of opioid antagonist prodrugs
|
EP1404342A1
(de)
|
2001-04-26 |
2004-04-07 |
Ortho-Mcneil Pharmaceutical, Inc. |
Behandlung psychotischer störungen mit gleichzeitiger therapie mit antikonvulsiven derivaten und atypischen antipsychotika
|
EP1262196A3
(de)
|
2001-05-23 |
2002-12-18 |
Pfizer Products Inc. |
Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht
|
US6960357B2
(en)
|
2001-05-25 |
2005-11-01 |
Mistral Pharma Inc. |
Chemical delivery device
|
AU2002305758B2
(en)
|
2001-06-01 |
2006-09-07 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company |
Pharmaceutical compositions for the coordinated delivery of NSAIDs
|
JP2004534056A
(ja)
|
2001-06-08 |
2004-11-11 |
エンドー ファーマシューティカルズ, インコーポレイティド |
アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス
|
US6462237B1
(en)
|
2001-06-14 |
2002-10-08 |
Usv Limited |
Cyclodextrin stabilized pharmaceutical compositions of bupropion hydrochloride
|
US7842307B2
(en)
|
2001-08-06 |
2010-11-30 |
Purdue Pharma L.P. |
Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
|
ES2326794T3
(es)
|
2001-08-06 |
2009-10-20 |
Euro-Celtique S.A. |
Formulaciones de agonistas opioides con antagonista liberable y secuestrado.
|
KR20040060917A
(ko)
|
2001-08-06 |
2004-07-06 |
유로-셀티크 소시에떼 아노뉨 |
오피오이드 남용을 방지하기 위한 조성물 및 방법
|
US20030087896A1
(en)
*
|
2001-08-09 |
2003-05-08 |
Hillel Glover |
Treatment of refractory depression with an opiate antagonist and an antidepressant
|
US20030044462A1
(en)
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
US6576256B2
(en)
|
2001-08-28 |
2003-06-10 |
The Brigham And Women's Hospital, Inc. |
Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
|
US20030091630A1
(en)
|
2001-10-25 |
2003-05-15 |
Jenny Louie-Helm |
Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
|
US6481031B1
(en)
|
2001-11-14 |
2002-11-19 |
In Mo Hwang |
Pillow oriented for comfort in varying sleeping positions
|
ITFI20010230A1
(it)
|
2001-11-29 |
2003-05-29 |
Menarini Int Operations Lu Sa |
Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
|
MXPA04006163A
(es)
|
2001-12-20 |
2004-11-01 |
Pharmacia Corp |
Formas de dosis de liberacion sostenida del orden-cero y metodo de fabricacion de las mismas.
|
US20040102440A1
(en)
|
2002-07-01 |
2004-05-27 |
Wong Erik Ho Fong |
Method of promoting smoking cessation
|
US6682759B2
(en)
|
2002-02-01 |
2004-01-27 |
Depomed, Inc. |
Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
|
US20040029941A1
(en)
|
2002-05-06 |
2004-02-12 |
Jennings Julianne E. |
Zonisamide use in obesity and eating disorders
|
RU2341259C2
(ru)
|
2002-05-17 |
2008-12-20 |
Дюк Юниверсити |
Способ лечения ожирения
|
US20050215552A1
(en)
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
CN101310723A
(zh)
|
2002-05-17 |
2008-11-26 |
迪欧加药品公司 |
有效的选择性阿片受体调制剂化合物的用途
|
US20040005368A1
(en)
|
2002-07-01 |
2004-01-08 |
Morris Mann |
Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
|
US6972291B2
(en)
|
2002-07-02 |
2005-12-06 |
Bernstein Richard K |
Method for reducing food intake
|
US20040258757A1
(en)
|
2002-07-16 |
2004-12-23 |
Elan Pharma International, Ltd. |
Liquid dosage compositions of stable nanoparticulate active agents
|
AU2003253925A1
(en)
|
2002-07-18 |
2004-02-09 |
Banyu Pharmaceutical Co., Ltd. |
Combination therapy for the treatment of obesity
|
US7086532B2
(en)
|
2003-07-16 |
2006-08-08 |
Allergan, Inc. |
Titration/compliance pack with increasing doses
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
US7985422B2
(en)
|
2002-08-05 |
2011-07-26 |
Torrent Pharmaceuticals Limited |
Dosage form
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
US7713551B2
(en)
|
2002-09-11 |
2010-05-11 |
Elan Pharma International Ltd. |
Gel stabilized nanoparticulate active agent compositions
|
US7273884B2
(en)
|
2002-09-13 |
2007-09-25 |
Eisai, Inc. |
Method of treating tremors
|
EP1556091A1
(de)
|
2002-10-04 |
2005-07-27 |
Elan Pharma International Limited |
Gamma-bestrahlung von festen aktivmaterialien in nanopartikularer form
|
US20040092504A1
(en)
|
2002-11-12 |
2004-05-13 |
Anuthep Benja-Athon |
Definitive medications for treating fibromyalgia
|
US6893660B2
(en)
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
US20040115265A1
(en)
|
2002-12-11 |
2004-06-17 |
Loutfy Benkerrour |
Multilayered tablet containing pravastatin and aspirin and method
|
AU2003296672A1
(en)
|
2002-12-13 |
2004-07-09 |
Cilag Ag |
Controlled release preparations comprising tramadol and topiramate
|
CA2414500A1
(en)
|
2002-12-17 |
2004-06-17 |
Purepharm Inc. |
Agonist-aversive combination medicines
|
AU2003303631B2
(en)
|
2002-12-26 |
2008-05-29 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company |
Multilayer Dosage Forms Containing NSAIDs and Triptans
|
US20040185097A1
(en)
|
2003-01-31 |
2004-09-23 |
Glenmark Pharmaceuticals Ltd. |
Controlled release modifying complex and pharmaceutical compositions thereof
|
WO2004071423A2
(en)
|
2003-02-05 |
2004-08-26 |
Euro-Celtique S.A. |
Methods of administering opioid antagonists and compositions thereof
|
US20040158194A1
(en)
|
2003-02-06 |
2004-08-12 |
Wolff Andy And Beiski Ben Z. |
Oral devices and methods for controlled drug release
|
WO2004078113A2
(en)
*
|
2003-03-04 |
2004-09-16 |
Pharmacia Corporation |
Treatment and prevention of obesity with cox-2 inhibitors alone or in combination with weight-loss agents
|
EP1772147A2
(de)
|
2003-03-17 |
2007-04-11 |
Japan Tobacco, Inc. |
Methode zur Verbesserung der oralen Bioverfügbarkeit von S-[2-([[1-(2-Ethylbutyl)Cyclohexyl]Carbonyl]Amino)Phenyl]-2-Methylpropanthioat
|
WO2004087175A1
(en)
|
2003-04-04 |
2004-10-14 |
Pharmacia Corporation |
Oral extended release compressed tablets of multiparticulates
|
EP1613324A2
(de)
|
2003-04-14 |
2006-01-11 |
Pain Therapeutics, Inc. |
Verfahren zur behandlung von schmerzen mit opioid-antagonisten
|
MY135852A
(en)
|
2003-04-21 |
2008-07-31 |
Euro Celtique Sa |
Pharmaceutical products
|
RU2350327C2
(ru)
|
2003-04-29 |
2009-03-27 |
Ориксиджен Серапьютикс, Инкорпорэйтд |
Составы, вызывающие потерю веса
|
WO2004100956A1
(en)
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Method for enhancing cognition using ziprasidone
|
CA2525366A1
(en)
|
2003-05-16 |
2004-11-25 |
Pfizer Products Inc. |
Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines
|
US20070099884A1
(en)
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
WO2004110368A2
(en)
|
2003-06-06 |
2004-12-23 |
Merck & Co., Inc. |
Combination therapy for the treatment of hypertension
|
US20060148721A1
(en)
|
2003-06-06 |
2006-07-06 |
Erondu Ngozi E |
Combination therapy for the treatment of dyslipidemia
|
US20050013863A1
(en)
|
2003-07-18 |
2005-01-20 |
Depomed, Inc., A Corporation Of The State Of California |
Dual drug dosage forms with improved separation of drugs
|
EP1663179A1
(de)
|
2003-07-21 |
2006-06-07 |
Noven Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur kontrolle der arzneimittelabgabe von silikon-klebemischungen
|
US7759358B2
(en)
|
2003-07-23 |
2010-07-20 |
Crooks Peter A |
Oral bioavailable prodrugs
|
CA2534924A1
(en)
|
2003-08-08 |
2005-02-24 |
Elan Pharma International Ltd. |
Novel metaxalone compositions
|
ATE454138T1
(de)
|
2003-08-08 |
2010-01-15 |
Biovail Lab Int Srl |
Tablette mit modifizierter freisetzung von bupropion hydrochlorid
|
US20050043704A1
(en)
|
2003-08-21 |
2005-02-24 |
Eisai Co., Ltd |
Methods of using zonisamide as an adjunctive therapy for partial seizures
|
US20050043773A1
(en)
|
2003-08-21 |
2005-02-24 |
Ivan Lieberburg |
Methods of improving the safety of zonisamide therapy
|
KR100965580B1
(ko)
*
|
2003-08-21 |
2010-06-23 |
엘지디스플레이 주식회사 |
액정표시장치와 그의 구동방법
|
US20050112211A1
(en)
|
2003-08-21 |
2005-05-26 |
Eric Gervais |
Micronutrient supplement
|
US20050043705A1
(en)
|
2003-08-21 |
2005-02-24 |
Eisai Co., Ltd. |
Methods of using zonisamide as an adjunctive therapy for partial seizures
|
US20060194826A1
(en)
|
2003-09-25 |
2006-08-31 |
Euro-Celtique S.A. |
Pharmaceutical combinations of hydrocodone and naltrexone
|
US20050112198A1
(en)
|
2003-10-27 |
2005-05-26 |
Challapalli Prasad V. |
Bupropion formulation for sustained delivery
|
US20050096311A1
(en)
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
US20050147664A1
(en)
|
2003-11-13 |
2005-07-07 |
Elan Pharma International Ltd. |
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
|
US20070149451A1
(en)
|
2003-11-17 |
2007-06-28 |
Holmes David G |
Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent
|
WO2005049043A1
(en)
|
2003-11-18 |
2005-06-02 |
Ortho-Mcneil Pharmaceutical, Inc. |
Combination therapy comprising metformin and anticonvulsant agents
|
US20050181049A1
(en)
|
2003-11-19 |
2005-08-18 |
Dong Liang C. |
Composition and method for enhancing bioavailability
|
CA2552221A1
(en)
|
2003-12-31 |
2005-07-21 |
Actavis Group Hf |
Donepezil formulations
|
US7713959B2
(en)
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
US7429580B2
(en)
|
2004-01-13 |
2008-09-30 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US20060160750A1
(en)
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US20050245460A1
(en)
|
2004-02-13 |
2005-11-03 |
Meyerson Laurence R |
Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
|
SE0400378D0
(sv)
|
2004-02-17 |
2004-02-17 |
Jan Hedner |
Sätt att behandla och diagnostisera andningsstörningar i sömnen och medel för att utföra sättet
|
EP1720527A2
(de)
|
2004-03-03 |
2006-11-15 |
Teva Pharmaceutical Industries Ltd |
Stabile pharmazeutische zusammensetzung mit einem säurelabilen arzneimittel
|
US20050245541A1
(en)
|
2004-03-19 |
2005-11-03 |
Elliot Ehrich |
Methods for treating alcoholism
|
US20060100205A1
(en)
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
WO2005110405A1
(en)
|
2004-05-03 |
2005-11-24 |
Duke University |
Compositions for affecting weight loss
|
US20050250838A1
(en)
|
2004-05-04 |
2005-11-10 |
Challapalli Prasad V |
Formulation for sustained delivery
|
BRPI0514060A
(pt)
|
2004-08-03 |
2008-05-27 |
Orexigen Therapeutics Inc |
combinação de bupropion e um segundo composto para acarretar a perda de peso
|
ES2539969T3
(es)
|
2004-08-25 |
2015-07-07 |
Essentialis, Inc. |
Formulaciones farmacéuticas de activadores del canal de potasio de ATP y usos de las mismas
|
CA2580694A1
(en)
|
2004-09-23 |
2006-03-30 |
Alexander Michalow |
Methods for regulating neurotransmitter systems by inducing counteradaptations
|
EP1804785A2
(de)
|
2004-10-27 |
2007-07-11 |
Neurogen Corporation |
Diaryl-harnstoffe als cb1-antagonisten
|
JP2008519078A
(ja)
|
2004-11-04 |
2008-06-05 |
ニューロゲン コーポレイション |
Cb1拮抗薬としてのアリールアルキル尿素類
|
WO2006055854A2
(en)
|
2004-11-17 |
2006-05-26 |
Cypress Bioscience, Inc. |
Methods for reducing the side effects associated with mirtazapine treatment
|
JP2006232675A
(ja)
|
2005-02-22 |
2006-09-07 |
Kowa Co |
複合型口腔内溶解用固形製剤
|
TW200716594A
(en)
|
2005-04-18 |
2007-05-01 |
Neurogen Corp |
Substituted heteroaryl CB1 antagonists
|
US20060246131A1
(en)
|
2005-04-28 |
2006-11-02 |
Cottlingham Elizabeth M |
Use of metformin to counteract weight gain associated with psychotropic medications
|
WO2006130522A2
(en)
*
|
2005-05-31 |
2006-12-07 |
Orexigen Therapeutics, Inc. |
Methods and compositions for managing psychotic disorders
|
US20070021352A1
(en)
|
2005-07-20 |
2007-01-25 |
Cypress Bioscience, Inc. |
Prevention and treatment of hearing disorders
|
EP1907005A1
(de)
|
2005-07-27 |
2008-04-09 |
Orexigen Therapeutics, Inc. |
Zusammensetzungen zur förderung von gewichtsverlust
|
JP5693817B2
(ja)
|
2005-08-19 |
2015-04-01 |
アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc |
糖尿病の治療法および体重の減少法
|
WO2007047351A2
(en)
|
2005-10-13 |
2007-04-26 |
Orexigen Therapeutics, Inc. |
Methods for treating hypertension in overweight and obese individuals
|
US20070099947A1
(en)
|
2005-11-03 |
2007-05-03 |
Alkermes, Inc. |
Methods and compositions for the treatment of brain reward system disorders by combination therapy
|
BRPI0618918B8
(pt)
|
2005-11-22 |
2021-05-25 |
Nalpropion Pharmaceuticals Llc |
uso de um primeiro composto e um segundo composto para tratar uma condição de glicose sanguínea
|
WO2007089318A2
(en)
|
2005-11-23 |
2007-08-09 |
Orexigen Therapeutics, Inc. |
Compositions and methods for reducing food cravings
|
WO2007062228A1
(en)
|
2005-11-28 |
2007-05-31 |
Orexigen Therapeutics, Inc. |
Sustained-release formulation of zonisamide
|
US20070179168A1
(en)
|
2005-11-28 |
2007-08-02 |
Orexigen Therapeutics, Inc. |
Methods of treating anxiety disorders
|
WO2007084290A2
(en)
|
2006-01-12 |
2007-07-26 |
Orexigen Therapeutics, Inc. |
Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain
|
EP1813276A1
(de)
|
2006-01-27 |
2007-08-01 |
Euro-Celtique S.A. |
Manipulationssichere Dosierformen
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
PL2526932T3
(pl)
|
2006-06-19 |
2017-12-29 |
Alpharma Pharmaceuticals Llc |
Kompozycja farmaceutyczna
|
CA2693992C
(en)
|
2006-07-20 |
2017-01-31 |
Somaxon Pharmaceuticals, Inc. |
Methods of improving the pharmacokinetics of doxepin
|
US8682445B2
(en)
|
2006-07-28 |
2014-03-25 |
Cyberonics, Inc. |
Patient management system for treating depression using an implantable medical device
|
US8088786B2
(en)
|
2006-11-09 |
2012-01-03 |
Orexigen Therapeutics, Inc. |
Layered pharmaceutical formulations
|
RU2009116834A
(ru)
|
2006-11-09 |
2010-12-20 |
Ориксиджен Терапьютикс, Инкорпорэйтд Сша/Сша (Us) |
Способ введения лекарственных средств для снижения веса
|
GB2447949B
(en)
|
2007-03-29 |
2010-03-31 |
Renasci Consultancy Ltd |
A method for identifying a compound for treating a disorder or condition associated with dysfunction of monoamine neurotransmission
|
RU2342195C1
(ru)
|
2007-04-18 |
2008-12-27 |
Институт проблем комплексного освоения недр РАН |
Устройство для механоактивации сульфидсодержащих минеральных продуктов
|
WO2009035473A2
(en)
|
2007-09-13 |
2009-03-19 |
Sanfilippo Louis C |
Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
|
US8846053B2
(en)
|
2008-09-26 |
2014-09-30 |
Sdg, Inc. |
Orally bioavailable lipid-based constructs
|
EP2303025A4
(de)
|
2008-05-30 |
2012-07-04 |
Orexigen Therapeutics Inc |
Verfahren zur behandlung von eingeweidefettbeschwerden
|
ES2762113T3
(es)
|
2010-01-11 |
2020-05-22 |
Nalpropion Pharmaceuticals Inc |
Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
|
WO2012070043A1
(en)
|
2010-11-26 |
2012-05-31 |
Ramot At Tel-Aviv University Ltd. |
Method and composition for weight-gain management
|
RS65198B1
(sr)
|
2010-12-03 |
2024-03-29 |
Nalpropion Pharmaceuticals Llc |
Povećana biodostupnost leka u terapiji naltreksonom
|
CN103298462A
(zh)
|
2010-12-03 |
2013-09-11 |
奥雷西根治疗公司 |
降低暴食或强迫进食的方法
|
EP4104824A1
(de)
|
2012-06-06 |
2022-12-21 |
Nalpropion Pharmaceuticals LLC |
Zusammensetzung zur verwendung in einem verfahren zur behandlung von übergewicht und fettleibigkeit bei patienten mit hohem kardiovaskulärem risiko
|
US8969371B1
(en)
|
2013-12-06 |
2015-03-03 |
Orexigen Therapeutics, Inc. |
Compositions and methods for weight loss in at risk patient populations
|